ES2609993B1 - Peptide for the treatment of allergy - Google Patents

Peptide for the treatment of allergy Download PDF

Info

Publication number
ES2609993B1
ES2609993B1 ES201531341A ES201531341A ES2609993B1 ES 2609993 B1 ES2609993 B1 ES 2609993B1 ES 201531341 A ES201531341 A ES 201531341A ES 201531341 A ES201531341 A ES 201531341A ES 2609993 B1 ES2609993 B1 ES 2609993B1
Authority
ES
Spain
Prior art keywords
peptide
allergy
treatment
seq
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201531341A
Other languages
Spanish (es)
Other versions
ES2609993A1 (en
Inventor
Cristobalina Mayorga Mayorga
María José TORRES JAEN
Miguel Blanca Gómez
Francisco Javier ROJO MARCOS
Ainhoa MASCARAQUE GONZÁLEZ
Francisco Javier RAMOS SORIANO
Luis FERNÁNDEZ PACIOS
Araceli DÍAZ PERALES
David ANDREU MARTÍNEZ
Javier VALLE GARCÍA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Politecnica de Madrid
Universitat Pompeu Fabra UPF
Servicio Andaluz de Salud
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Politecnica de Madrid
Universitat Pompeu Fabra UPF
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Politecnica de Madrid, Universitat Pompeu Fabra UPF, Servicio Andaluz de Salud filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201531341A priority Critical patent/ES2609993B1/en
Priority to PCT/ES2016/070654 priority patent/WO2017051049A1/en
Publication of ES2609993A1 publication Critical patent/ES2609993A1/en
Application granted granted Critical
Publication of ES2609993B1 publication Critical patent/ES2609993B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Péptido para el tratamiento de la alergia.#La presente invención hace referencia a un péptido para el tratamiento de la alergia. Más específicamente una secuencia aminoacídica o peptídica (identificada en la presente invención como SEQ ID NO: 1) desarrollada a partir de varias regiones de la proteína Pru p 3. Adicionalmente, se refiere a un procedimiento para insertar dicha secuencia (SEQ ID NO: 1) en un sistema dendrítico. Dicho péptido de SEQ ID NO: 1 y complejo péptido-dendrímero proporcionan nuevas herramientas terapéuticas útiles, para la prevención, mejora, alivio y/o tratamiento de la alergia, concretamente de la alergia causada por el síndrome LTP.Peptide for the treatment of allergy. # The present invention refers to a peptide for the treatment of allergy. More specifically an amino acid or peptide sequence (identified in the present invention as SEQ ID NO: 1) developed from several regions of the Pru p 3 protein. Additionally, it refers to a method for inserting said sequence (SEQ ID NO: 1 ) in a dendritic system. Said peptide of SEQ ID NO: 1 and peptide-dendrimer complex provide new useful therapeutic tools, for the prevention, improvement, relief and / or treatment of allergy, specifically allergy caused by LTP syndrome.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

imagen27image27

imagen28image28

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4 imagen5image5 imagen6image6 imagen7image7
ES201531341A 2015-09-21 2015-09-21 Peptide for the treatment of allergy Expired - Fee Related ES2609993B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201531341A ES2609993B1 (en) 2015-09-21 2015-09-21 Peptide for the treatment of allergy
PCT/ES2016/070654 WO2017051049A1 (en) 2015-09-21 2016-09-20 Peptide derived from the pru p 3 allergen of prunus persica for the treatment of allergies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201531341A ES2609993B1 (en) 2015-09-21 2015-09-21 Peptide for the treatment of allergy

Publications (2)

Publication Number Publication Date
ES2609993A1 ES2609993A1 (en) 2017-04-25
ES2609993B1 true ES2609993B1 (en) 2018-02-07

Family

ID=58386056

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201531341A Expired - Fee Related ES2609993B1 (en) 2015-09-21 2015-09-21 Peptide for the treatment of allergy

Country Status (2)

Country Link
ES (1) ES2609993B1 (en)
WO (1) WO2017051049A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2607376A1 (en) * 2011-12-22 2013-06-26 Biomay Ag Hypoallergenic allergen derivatives of Pru p 3 for immunotherapy of IgE-mediated peach allergy
EP2813243B1 (en) * 2013-06-11 2017-08-09 Paris-Lodron-Universität Salzburg PRU p 3 mimicks

Also Published As

Publication number Publication date
WO2017051049A1 (en) 2017-03-30
ES2609993A1 (en) 2017-04-25

Similar Documents

Publication Publication Date Title
ES2871036T3 (en) Method for treating bile acid-related disorders
MX2016002154A (en) Respiratory syncytial virus (rsv) vaccine.
MX2017009595A (en) Anti-senescence compounds and uses thereof.
ES2721309T3 (en) Composition for preparing tagatose and method for preparing tagatose from fructose
BR112015030326A2 (en) ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM
EA201890815A1 (en) AMINO ACID COMPOSITIONS WITH MODIFIED DELIVERY FOR ORAL ADMINISTRATION
ES2722773T3 (en) Modified Meningococcal fHbp Polypeptides
AR120721A2 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE
WO2015107363A3 (en) Mycobacterial antigen composition
BR112017000135A2 (en) process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
BR112017018703A2 (en) peptide derived from gpc3, pharmaceutical composition for treating or preventing cancer using the same, inducing immunity, and method for producing antigen presenting cells
BR112017010832A2 (en) amino acid compositions for treating disease symptoms
BR112014028130A2 (en) HYDROchloride salt of a peptide, pharmaceutical composition, use of a hydrochloride salt, use of a pharmaceutical composition, and method of preventing or treating cat allergy
PE20230343A1 (en) PEPTIDES THAT STIMULATE ANTI-TUMORAL IMMUNE RESPONSES
BR112017006969A2 (en) hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using the same, immunity inducer and antigen presenting cell production method
EA201691498A1 (en) NEW TARGET FOR THE TREATMENT AND PREVENTION OF DIABETES
BR112016030604B8 (en) PROCESS FOR PREPARATION OF 3- HYDROXYPICOLINIC ACIDS
MX2018014966A (en) Protease-resistant mono-lipidated peptides.
WO2015043566A8 (en) Cyclic amyloid-beta-binding peptides and the use thereof
CO6362049A2 (en) PEPTIDO-EPITOPE RAB6KIFL / KIF20A AND VACCINES CONTAINING THE SAME
AR098615A1 (en) PEPTIDE FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
ES2609993B1 (en) Peptide for the treatment of allergy
AR098616A1 (en) PEPTIDE FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
JP2015129652A5 (en)
ES2545458T3 (en) PTEC fragments

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2609993

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20180207

FD2A Announcement of lapse in spain

Effective date: 20210929